lansoprazole has been researched along with Hyperplasia in 9 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis versus lansoprazole." | 9.69 | Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. ( Akiyama, J; Aoyama, N; Haruma, K; Kanoo, T; Kinoshita, Y; Kushima, R; Kusumoto, N; Miyata, K; Uemura, N; Yao, T, 2023) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 7.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 7.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| " The aim of this study was to assess the long-term safety of vonoprazan for maintenance treatment of healed erosive oesophagitis versus lansoprazole." | 5.69 | Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. ( Akiyama, J; Aoyama, N; Haruma, K; Kanoo, T; Kinoshita, Y; Kushima, R; Kusumoto, N; Miyata, K; Uemura, N; Yao, T, 2023) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 3.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 3.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Haruma, K | 1 |
| Kinoshita, Y | 1 |
| Yao, T | 1 |
| Kushima, R | 1 |
| Akiyama, J | 1 |
| Aoyama, N | 1 |
| Kanoo, T | 1 |
| Miyata, K | 1 |
| Kusumoto, N | 1 |
| Uemura, N | 1 |
| East, JE | 1 |
| Vieth, M | 2 |
| Rex, DK | 1 |
| Matsuzaki, J | 1 |
| Suzuki, H | 1 |
| Minegishi, Y | 1 |
| Sugai, E | 1 |
| Tsugawa, H | 1 |
| Yasui, M | 1 |
| Hibi, T | 1 |
| Fukushima, Y | 1 |
| Shindo, T | 1 |
| Anai, M | 1 |
| Saitoh, T | 1 |
| Wang, Y | 1 |
| Fujishiro, M | 1 |
| Ohashi, Y | 1 |
| Ogihara, T | 1 |
| Inukai, K | 1 |
| Ono, H | 1 |
| Sakoda, H | 1 |
| Kurihara, Y | 1 |
| Honda, M | 1 |
| Shojima, N | 1 |
| Fukushima, H | 1 |
| Haraikawa-Onishi, Y | 1 |
| Katagiri, H | 1 |
| Shimizu, Y | 1 |
| Ichinose, M | 1 |
| Ishikawa, T | 1 |
| Omata, M | 1 |
| Nagai, R | 1 |
| Kurihara, H | 1 |
| Asano, T | 1 |
| Eissele, R | 1 |
| Brunner, G | 1 |
| Simon, B | 1 |
| Solcia, E | 1 |
| Arnold, R | 1 |
| Suzuki, S | 2 |
| Ohkusa, T | 2 |
| Shimoi, K | 2 |
| Horiuchi, T | 2 |
| Fujiki, K | 2 |
| Takashimizu, I | 2 |
| Sakurazawa, T | 1 |
| Ariake, K | 1 |
| Ishii, K | 1 |
| Kumagai, J | 1 |
| Tanizawa, T | 1 |
| Hirschowitz, BI | 1 |
| Haber, MM | 1 |
| Stolte, M | 1 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| Seifert, E | 1 |
1 review available for lansoprazole and Hyperplasia
| Article | Year |
|---|---|
Serrated lesions in colorectal cancer screening: detection, resection, pathology and surveillance.
Topics: Adenomatous Polyposis Coli; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Early Detection of Ca | 2015 |
3 trials available for lansoprazole and Hyperplasia
| Article | Year |
|---|---|
Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Esophagitis; Humans | 2023 |
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; | 1998 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
5 other studies available for lansoprazole and Hyperplasia
| Article | Year |
|---|---|
Acid suppression by proton pump inhibitors enhances aquaporin-4 and KCNQ1 expression in gastric fundic parietal cells in mouse.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Aquaporin 4; Blotting, Western; Cell Differentiati | 2010 |
Structural and functional characterization of gastric mucosa and central nervous system in histamine H2 receptor-null mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Blotting, Northern; Electroshock; Gastric Acid; Ga | 2003 |
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Gastric Mucosa; Gastrins; Gastritis; H | 1997 |
Disappearance of multiple hyperplastic polyps after the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati | 1997 |
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Enterochromaffin-like Cells; Enzyme Inhibitors; Fema | 2001 |